Beijing Establishes New Drug Innovation And Production Alliance
This article was originally published in PharmAsia News
To accelerate the commercialization of pharmaceutical technology and reverse the low market share of Beijing-made drugs, Peking University, Beijing Pharmaceutical Group, Beijing Pharmaceutical Profession Association and 13 other Beijing-based biopharmaceutical institutions have officially formed an industry research alliance. Based on an open system, the enterprises and academic institutions will bring in more organizations to co-develop innovative products within the group. The alliance will focus on setting up a platform in four areas: new drug pilots, guidance for clinical trials, new product R&D and commercialization, and talent cultivation. (Click here for more - Chinese Language)
You may also be interested in...
Abbott reported strong sales for diagnostics and devices in the third quarter and raised its full-year EPS guidance to $3.55 per share.
Vifor CEO Stefan Schulze tells Scrip that an expanded deal with Korsuva developer Cara Therapeutics means the US biotech will not have to invest in a commercial organization as the Swiss firm will mobilize its well-established sales force to launch the treatment for dialysis patients with CKD-associated pruritus.
A randomized trial demonstrated the superiority of Medtronic’s DTM spinal cord stimulation waveform over conventional spinal cord stimulation for treating back pain.